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Type 2 diabetesA B S T R A C T
Aim: To provide information on the extent to which type 2 diabetes more likely induced by
statins affects the risk of macrovascular complications compared to diabetes unlikely
induced by statins.
Methods: The 84,828 residents in the Italian Lombardy Region who were newly treated with
statins between 2003 and 2005 were followed from the index statin prescription until 2009
(step-1 follow-up) to identify those starting antidiabetic therapy. The proportion of days of
follow-up covered by statins measured adherence with statins. Cohort members who expe-
rienced diabetes were 1:3 matched with those who did not developed diabetes for gender,
age and previous adherence with statin treatment. The 3321 diabetic - non-diabetic sets,
were followed from the initial antidiabetic therapy until 2012 (step-2 follow-up) to estimate
the hazard ratio (HR), and 95% Confidence Interval (CI), for macrovascular complications
(proportional hazard models) associated with diabetes separately in each category of
adherence with statins.
Results: During the step-1 follow-up, the risk of new-onset diabetes increased progressively
with increasing adherence with statins. During the step-2 follow-up, the risk of macrovas-
cular complications associated with diabetes decreased progressively from 1.70 (1.18–2.44),
1.41 (1.17–1.70), 1.30 (1.07–1.57) until 1.10 (0.40–2.80) as adherence with statins during the
step-1 follow-up increased.ailure; MI,
s covered;
occa degli
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 3 3 ( 2 0 1 7 ) 6 0 –6 8 61Conclusions: Type 2 diabetes lost its association with increasing macrovascular risk when
previous adherence with statins was very high, and thus the chance of its induction by
the drug greater. Statin-dependent type 2 diabetes might be prognostically less adverse
than diabetes unlikely induced by statins.
 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
A large number of studies has shown that use of statins is
accompanied by an increased risk of developing type 2 dia-
betes [1–5], which is thus currently listed as an inconve-
nience of these drugs that may attenuate in some patients
their protective effect. However, several aspects of the
statin-induced diabetes have not been adequately clarified.
For example, albeit several hypotheses have been advanced,
the mechanisms through which statins favour the alteration
of glucose metabolism that leads to the appearance of
hyperglycaemia and diabetes remain unclear [4,6]. Further-
more, although statin-induced diabetes is generally believed
not to offset the protective lipid-lowering effect of statins
on the cardiovascular (CV) system [7–9], limited information
exists on whether statin-induced diabetes has the same
adverse prognostic significance of diabetes unlikely induced
by statins, i.e., whether it is associated with a similar
increasing risk of diabetes-related macrovascular complica-
tions. This information is of fundamental importance to
reliably quantify the impact of statin-induced diabetes on
the role played by statins on primary and secondary CV pre-
vention [10,11].
We have previously shown that at the population level
an increasing adherence with statin treatment is accompa-
nied by a clear-cut progressive increase in the risk of new
onset type 2 diabetes [12]. The purpose of the present
study was to provide information on the extent to which
diabetes more likely to be induced by statins affects the
risk of macrovascular complications to a similar or differ-
ent degree compared to diabetes unlikely induced by
statins.
2. Subjects, materials and methods
2.1. Setting
The data used for this study were retrieved from the health-
care utilization databases of Lombardy, a Region of Italy
which accounts for about 16% (almost ten million) of its
population. In Italy, the whole population is covered by
the National Health Service and in Lombardy this has been
associated since 1997 with an automated system of data-
bases to collect a variety of information. A detailed descrip-
tion of the healthcare utilization databases of the Lombardy
Region for studying the association between lipid lowering
and antidiabetic treatments is available in previous studies
[12,13].2.2. Cohort selection and follow-up – step-1
The study was designed according to the procedure shown in
Fig. 1, upper part. All the 651,552 beneficiaries of the National
Health Service who had their residence in Lombardy were
identified, provided that their age was between 40 and
80 years and at least one prescription of statins had been dis-
pensed between 2003 and 2005. The date of the first dispensa-
tion was considered as the step-1 index date.
Four patient categories were excluded: (i) the 372,302
patients who received one or more statin prescriptions within
three years prior the step-1 index date; (ii) the 51,912 patients
who received at least one antidiabetic agent, or were hospital-
ized with a diagnosis of diabetes, within the three years
before the step-1 index date; (iii) the 70,827 patients who were
hospitalized for CV disease or received prescriptions of CV
drugs such as nitrates or digitalis within the three years
before the step-1 index date; and (iv) the 71,683 patients
who did not renew the initial prescription of statins and/or
did not reach at least one year of follow-up.
The remaining 84,828 patients represented the step-1
cohort, each of its members accumulating person-years of
follow-up from the step-1 index date until the earliest among
the dates of starting antidiabetic drug therapy (step-1 out-
come, see below) or censoring, e.g. death from any cause,
emigration or step-1 phase stopping (i.e., December 31st
2009). The step-1 outcome was the appearance of diabetes
as diagnosed by the prescription of antidiabetic drugs. To
minimize the risk of false positive diabetic cases, three antidi-
abetic drug prescriptions were required for the ascertainment
of step-1 outcome onset.
2.3. Cohort selection and follow-up – step-2
As shown in Fig. 1, lower part, the 4391 step-1 cohort mem-
bers who experienced the step-1 outcome and the 77,893
statin-treated patients who did not have any antidiabetic drug
dispensation were considered eligible for inclusion in the
step-2 cohort. For each cohort members who experienced
the step-1 outcome (who we assumed to be diabetics), up to
three patients without signs of diabetes were randomly
selected from the corresponding cohort to be matched for
gender, age at cohort entry (±1 year), step-1 index date
(±30 days) and adherence with statin therapy (see below).
Patients without signs of diabetes were assumed to be at risk
of diabetes when the matched patient with diabetes suffered
from it. To minimize the chance of outcomes (see below)
unrelated to diabetes, the 1070 sets (each formed by 1 patient
Fig. 1 – Flow-chart of selection of the cohorts.
Footnote: NHS: National Health Service; CV: Cardiovascular.
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experienced a hospitalization for CV disease during the step-1
follow-up were excluded. The remaining 3321 diabetic and
non-diabetic matched sets represented the step-2 cohort,
each of its members accumulating person-years of follow-
up from the date of the first antidiabetic drug prescription
(i.e., the step-2 index date), until the earliest among the dates
of step-2 outcome (first admission to public or private hospi-
tals for macrovascular complications), death from any cause,
emigration, or December 31st 2012. Macrovascular complica-
tions included myocardial infarction, peripheral vascular dis-
ease, myocardial revascularization, heart failure and
cerebrovascular disease requiring hospitalization, as reported
by the diagnosis at discharge from hospital. The diagnostic
codes employed are reported in the Supplementary Table S1.
2.4. Adherence with medications
All prescriptions of statins dispensed to the cohort members
during the step-1 follow-up were identified. The period cov-
ered by a prescription was calculated from the number oftablets in the dispensed canisters, assuming a treatment
schedule of one tablet per day [14]. For overlapping prescrip-
tions, a patient was assumed to have used all tablets of the
previous canister before starting to use the newer one. Adher-
ence with therapy was quantified as the cumulative number
of days during which the medication was available divided
by the number of days of follow-up, i.e., the ‘‘proportion of
days covered” (PDC) by treatment [15]. The antidiabetic and
antihypertensive drugs dispensed to the statin-treated
patients with diabetes during their follow-up were identified
as well, and adherence with these treatments was also quan-
tified through the PDC calculation. The codes used to identify
therapeutic categories are reported in the Supplementary
Table S1.
2.5. Additional information
At the step-1 index date, data included (1) the type of the
prescribed statin (atorvastatin, fluvastatin, lovastatin,
pravastatin, rosuvastatin or simvastatin); (2) previous use of
antihypertensive, antiarrhythmic, antithrombotic and
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anti-inflammatory drugs and drugs used for chronic obstruc-
tive lung disease; and (3) the Charlson comorbidity index
score [16], which was calculated from the diagnostic informa-
tion available from inpatient charts in the three years prior
the step-1 index date. At the step-2 index date information
also included adherence with statins during the step-1
follow-up as well as with antidiabetic agents during the
step-2 follow-up.
2.6. Data analysis
A two-stage data analysis was employed. In the first stage, we
looked for replication of our previous findings [12] that
increasing the level of adherence with statins increases the
risk of developing diabetes (the step-1 outcome), using the
step-1 cohort. The Cox proportional hazard regression was
used to estimate the hazard ratio (HR), and the 95% CI, of dia-
betes associated with adherence with statins. Adherence was
quantified by four PDC categories, i.e. a very low (PDC  10%),
low (PDC from 11% to 50%), intermediate (PDC from 51% to
89%) and high (PDC  90%) adherence with statins. The first
category included patients who almost never used statins
while the last one those who almost always used these drugs,
which made the chance for new onset diabetes to be drug
dependent very low and very high, respectively. Because drug
exposure may vary over time, adherence categories were
included in the model as time-dependent variables, thereby
accounting for their cumulative and varying nature. The
model included as covariates those above listed as additional
information considered at step-1 index date.
The second-stage data analysis focused on whether the
greater or lesser chance for diabetes to be induced by statins
translated into a different risk of macrovascular complica-
tions. To this aim, the 3321 matched sets forming the step-2
cohort were stratified according to the four categories of
adherence with statins used for the step-1 follow-up. The
overall risk of macrovascular complications associated with
the diabetic condition was calculated for the entire cohort,
as well as separately in each category of adherence with sta-
tins, using the HR, and 95% CI, derived from the Cox propor-
tional hazard model. The risk of each specific
macrovascular complication was also estimated provided
that the incidence at least 200 cases was available (being
the limitation adopted to ensure against a two-sided type I
error of 0.05 and a HR of at least 1.5, with a power of 0.80).
Aforementioned covariates (with the exclusion of matching
variables), both as time-fixed (those measured at the step-1
index date) and time dependent (those measured during the
step-2 follow-up) variables, were included in the model.
We assumed that: (i) the likelihood that diabetes was
induced by statins would increase from the lowest to the
highest category of adherence with statins; (ii) because dia-
betic and non-diabetic patients were matched for statin
adherence, the HRs of macrovascular complications would
not be affected by statins and (iii) if the adverse prognostic
significance of statin-induced diabetes was similar to that of
diabetes not due to statin, the risk of macrovascular compli-
cations associated with diabetes would be similar in all cate-
gories of adherence with statins. It would, on the other hand,show a progressive attenuation of the risk of macrovascular
complications associated with diabetes along categories of
increasing adherence with statins if the adverse prognostic
significance of statin-induced diabetes was less adverse than
that of diabetes unlikely due to statins. Statistically talking,
this is equivalent to test the null hypothesis that the HRs of
macrovascular complications (on logarithmic scale) do not
vary linearly along the categories of adherence with statins.
Two ancillary analyses were performed to check whether
interpretation of the risk of macrovascular complications in
diabetic patients with a different adherence with statins
might be affected by (i) a delayed protective effect of statins
dispensed during the step-1 follow-up and/or (ii) the exclu-
sion of patients with CV events during the step-1 follow-up
or before the inclusion in the study, with thus a selection of
those less susceptible to the protective effect of the drug.
The former possibility was addressed by calculating the risk
of macrovascular complications at different degrees of adher-
encewith statins starting 3 or 6 years after the initial drug dis-
pensation in order to verify whether the CV outcomes
observed in the step-2 follow-up may be affected by the
adherence with statins during the step-1 follow-up. The latter
possibility was addressed by including in the analysis also
patients experiencing hospitalizations for CV events during
the step-1 follow-up or in the 3 years before the step-1 index
date.
The Statistical Analysis System Software (version 9.4; SAS
Institute, Cary, North Carolina, USA) was used to perform the
analyses. For all hypotheses tested, two-tailed p-values less
than 0.05 were considered to be significant.3. Results
3.1. New onset diabetes under statin treatment – step-1
The 84,828 patients belonging to the step-1 cohort accumu-
lated 467,317 person-years of follow-up, on average 5.5 years
per patient. During this period 6935 patients exhibited new
onset diabetes (the step-1 outcome) with an incidence of
14.8 cases every 1000 person-years. The characteristics of
step-1 cohort members according to whether they developed
or did not develop diabetes are reported in Table 1. Compared
with patients who did not develop diabetes, those developing
diabetes were older, more often males, and more often under
atorvastatin, as well as other drug treatments (antihyperten-
sive, antithrombotic, anti-inflammatory and respiratory
agents). Patients who developed diabetes also exhibited an
overall higher adherence with statins than patients who did
not develop diabetes.
As shown in Fig. 2, the risk of developing diabetes raised
progressively and significantly as adherence with statins
increased. Compared to patients with very low adherence,
the increase was 24% (95% CI: 12–37%), 72% (95% CI: 56–
90%), and 95% (95% CI: 60–139%) for patients with low, inter-
mediate and high adherence, respectively. Assuming that
among patients with very low adherence, diabetes was
entirely unrelated to use of statins, the proportion of diabetes
attributable to use of statins [17,18] was 19% (95% CI: 11–27%),
42% (36–47%) and 49% (38–58%) for patients with low,
Table 1 – Characteristics of the 84,828 step-1 cohort members according to whether they developed or did not develop
diabetes (antidiabetic drug therapy initiation) during the step-1 follow-up.
New onset diabetes (n = 6935) No new onset diabetes (n = 77,893) p-Valuea
Baseline
Men 3300 (47.6%) 31,718 (40.7%) <0.0001
Age: mean (SD) 62.4 (8.7) 61.4 (9.2) <0.0001
Initial therapy with statins
Atorvastatin 2224 (32.0%) 24,082 (30.9%) 0.0021
Fluvastatin 804 (11.6%) 8782 (11.3%)
Lovastatin 46 (0.7%) 530 (0.7%)
Pravastatin 1024 (14.8%) 11,927 (15.3%)
Rosuvastatin 896 (12.9%) 11,397 (14.6%)
Simvastatin 1941 (28.0%) 21,175 (27.2%)
Previous use of other drugs
Fibrates 12 (0.2%) 51 (0.1%) 0.0963
Antihypertensive agents 4756 (68.6%) 44,037 (56.5%) <0.0001
Antiarrhythmic agents 145 (2.1%) 1668 (2.1%) 0.7803
Antithrombotic agents 2137 (30.8%) 19,988 (25.7%) <0.0001
Drugs for COPD 1582 (22.8%) 16,331 (21.0%) 0.0003
NSAIDs 3966 (57.2%) 41,950 (53.9%) <0.0001
Antidepressant agents 931 (13.4%) 9866 (12.7%) 0.0693
Charlson comorbidity index score  1 220 (3.2%) 2312 (3.0%) 0.3384
During the step-1 follow-up
Categories of PDCb
10% 1091 (15.7%) 17,732 (22.8%) <0.0001
11–50% 2868 (41.4%) 32,094 (41.2%)
51–90% 2830 (40.8%) 26,957 (34.6%)
>90% 146 (2.1%) 1110 (1.4%)
a Value according to chi-square (gender, initial therapy with statins, previous use of other drugs and Charlson comorbidity index score), its
version for the trend (categories of PDC) or t test for independent samples (mean age).
b PDC: proportion of days covered by treatment with statins.
Fig. 2 – Effect of adherence with statin therapy on the hazard ratio (HR) of new onset diabetes during the step-1 follow-up.
Footnote. Adherence with statins therapy is categorized as very low (10%), low (11–50%), intermediate (51–89%) and high
(90%) proportion of days covered (PDC) by statin prescription. HR of diabetes onset, and corresponding 95% CI, was
estimated according to Cox proportional hazard model. Adjustments were made for age (continuous), gender, type of statin
therapy, concomitant use of other drugs, history of CV disease and categories of Charlson comorbidity index score.
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This means that the greater is the adherence with statins
the greater is the likelihood of the diabetic condition to be
induced by statin use.
3.2. Diabetes complications in patients with new onset
diabetes – step-2
The 3321 matched sets of diabetic and non-diabetic patients
belonging to the step-2 cohort accumulated 65,833 person-
years of follow-up, on average 5.1 years per patient. During
this period 376 and 760 diabetic and non-diabetic patients
respectively experienced the step-2 outcome, the correspond-
ing incidence being 22.8 and 15.4 hospitalizations every 1000
person-years (6.5 and 4.6 for myocardial infarction, 2.2 and
1.2 for peripheral vascular disease, 10.0 and 6.6 for myocardial
revascularization, 3.7 and 1.9 for heart failure and 8.2 and 6.2
for cerebrovascular disease). Among the 3321 diabetics, 381,
1422, 1433 and 85 had very low, low, intermediate and high
adherence with statins, respectively.
As step-1 adherence with statins increased, diabetics
included in step-2 follow-up were trendily older, started
lipid-lowering therapy with rosuvastatin (and less with
pravastatin and simvastatin) and were on treatment with
antihypertensive and antithrombotic agents (Supplementary
Table S4).
The step-2 adherence with antidiabetic drugs was similar
regardless the adherence with statins exhibited in the previ-
ous step-1 follow-up, the mean PDC (SD) values being 50%
(26), 49% (26), 53% (25) and 55% (26) for diabetic patients with
very low, low, intermediate and high adherence with statins,
respectively. This was also the case for the step-2 adherence
with antihypertensive drugs, the mean PDC (SD) values being
68% (31), 76% (28), 69% (31) and 71% (22), respectively. Further-
more, the mean age (SD) at the cohort entry (i.e., when statin
treatment started) in the four groups of step-1 statin adher-
ence was, respectively, 60.8 (8.9), 61.5 (8.4), 61.8 (8.0) and 62.6
(8.4) years.
In the entire cohort, patients with diabetes had a risk of
macrovascular complications 39% (95% CI, 23–57%) higher
than that of patients without diabetes. As shown in Supple-
mentary Table S5, cotreatment with antihypertensive,
antithrombotic agents, and presence of comorbidities, sig-
nificantly contributed to increase the risk of the macrovas-
cular complications. As shown in the top panel of Fig. 3,
the potential of diabetes for inducing macrovascular com-
plications in step-2 follow-up, decreased with the increasing
adherence to statins in step-1 follow-up, the risk excess
being 70% (95% CI: 18–144%), 41% (17–70%), 30% (7–57%)
and 10% (60% to 180%) for very low, low, intermediate
and high adherence, respectively (p-trend = 0.0384). This
trend was similar for the specific events separately consid-
ered, for all of which the diabetes-related risk was much
less in patients with a high as compared to low adherence:
112% vs. 15% for myocardial infarction, 65% vs. 28% for
myocardial revascularization and 40% vs. 13% for cere-
brovascular disease (Fig. 3, bottom panel).3.3. Ancillary analyses
Supplementary Table S2 shows that the difference in the risk
of CV events along categories of adherence with statins in the
step-1 follow-up, decreased and disappeared by delaying the
start of follow-up, respectively by 3 and 6 years from the ini-
tial statin dispensation. This suggests that the risk of CV out-
comes is probably not affected by the previous adherence
with statins.
Supplementary Table S3 shows that the difference in the
diabetes-related excess CV risk between the categories of very
low and high adherence with statins (large and small or
absent excess risk, respectively) was similar regardless the
exclusion or inclusion of patients with events in the step-1
follow-up. This suggests that our main finding was not
affected by the selective inclusion of patients who did not
experience CV events before the step-2 index date.
4. Discussion
To obtain information on the prognostic significance of statin-
induced diabetes vs. diabetes not due to statins we assumed
that the probability for diabetes to be induced by statins
would increase progressively as adherence with statins
increased. We further assumed that, this being the case, in
statin-treated patients developing diabetes the risk of
macrovascular complications would exceed that of statin-
treated patients without diabetes (1) similarly at all levels of
adherence with statin treatment, if statin-induced diabetes
and diabetes not due to statins are prognostically similar
and (2) less as adherence with statin treatment increases if
statin-induced diabetes is prognostically less adverse than
diabetes not due to statins. Our finding that, compared to
statin-treated patients without diabetes, statin-treated
patients developing diabetes exhibited a progressively lower
macrovascular risk as adherence with statins increased, is
compatible with the latter possibility, leading to the sugges-
tion that the adverse prognostic consequences of diabetes
may be attenuated if this condition is induced by or associ-
ated with statins, its clinical nature thus being more benign.
This finds a particularly clear support in the observation that
in patients with an almost complete adherence with statins
(>90%) new onset diabetes did not differ prognostically from
the non-diabetes status whereas in patients with very low
adherence (<10%) with statins the excess risk of new diabetic
patients was about two fold higher than that of non-diabetic
patients.
Other possible explanations of our findings need to be dis-
cussed. One explanation is that, adherence with statins
reflected adherence to other drugs, i.e. to antidiabetic and
antihypertensive agents, whose progressively greater thera-
peutic coverage during the step-2 follow-up might have been
responsible for the results. However, the antidiabetic drugs
that were prescribed in the Lombardy population have shown
only modest beneficial effects on macrovascular complica-
tions [19–22], which have recently been shown to be substan-
tially reduced by the administration of antidiabetic drugs [23–
Fig. 3 – Effect of diabetes on the hazard ratio (HR) of hospitalization for macrovascular complications according to step-1
adherence with statin therapy. Macrovascular complications on the whole and specific macrovascular outcomes (i.e.,
myocardial infarction, cerebrovascular disease and myocardial revascularization) are shown in top and bottom panel
respectively.
Footnote. Hazard ratio (HR) of hospitalization for macrovascular complications, and 95% CI, was estimated according to the
Cox proportional hazard model. Adjustments were made for covariates measured at the step-1 index date. Explanations and
symbols as in Fig. 2.
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thermore, and more importantly, we did not find that adher-
ence with antidiabetic agents during the step-2 follow-up
differed substantially among the categories of step-1 adher-
ence with statins that were analysed. This was the case also
for adherence with antihypertensive drug treatment, i.e. a
treatment with a documented protective effect in the large
fraction of the diabetic population with a blood pressure ele-
vation [26].
A second possible explanation is that the outcome pat-
terns seen in the step-2 follow-up were accounted for by an
extension of the protective effects of adherence with statins
in the step-1 phase of the study [27]. However, this should
have affected both diabetic and non-diabetic patients, with
no progressive attenuation and final disappearance of their
CV risk difference as adherence with statins increased, as it
was indeed the case. Moreover, patients included in the
step-2 cohort were those who did not experience CV hospital-
izations during the step-1 follow-up, making it unlikely that
an increased effect on the risk could appear later (see Supple-
mentary Table S2).
A third explanation is that the progressive reduction of the
excess risk of outcomes exhibited by newly diabetic patients
as adherence with statins increased reflects a greater protec-tive effect of statins in patients with diabetes compared to
those without diabetes. This might find support in the obser-
vation that in the step-2 follow-up the risk attenuation asso-
ciated with the increasing step-1 follow-up adherence was
greater in patients with diabetes than in those without dia-
betes, this being the case both in individuals without and in
individuals with hospitalization for CV events for several
years before as well as during the step-1 follow-up (i.e., low
and high risk categories in which the benefit of statins would
be expected to be small and large, respectively) (Supplemen-
tary Table S3, ancillary analysis). In this context, it should
be mentioned that in clinical trials the CV benefits of statins
have been found to be evident both with andwithout diabetes
[28,29]. It should also be mentioned that a greater protective
effect of statins in diabetes implies that the continuing use
of these drugs can therapeutically attenuate or even counter-
balance the risk associated with their diabetogenic influence,
thereby somehow coping with such specific inconvenience of
their administration.
Our study has strengths and limitations. It is one of the lar-
gest cohort studies on the association between statins and
new onset diabetes. This study has also examined the CV
consequences of this phenomenon on a large variety of CV
events over a reasonably long follow-up (on average 5.1 years
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status can be inferred (and the data adjusted for) from knowl-
edge of hospitalizations, treatments for CV disease and
assumption of non-CV drugs, information does not include
fasting serum glucose, lipid values, blood pressure and other
clinical variables, e.g. baseline LDL-C levels. In addition,
because the step-1 follow-up was not too long to influence
the effect of novel statin therapy (in average 5.5 years), it is
plausible that conventional risk factors of diabetes (i.e., those
unavailable in the database, such as high BMI and unhealthy
diet), may play an undetected (residual) role. However, we
must assume that these factors are positively associated with
statin adherence, in order they may act as confounders.
Another limitation of our study is that antidiabetic medica-
tion may be started for indications different to diabetes (i.e.,
metformin for prediabetes or polycystic ovarian syndrome),
albeit this misclassification would be likely small. Finally,
our conclusion that, compared to diabetes unlikely due to sta-
tins, statin-induced diabetes is prognostically more benign
holds for the follow-up of our study, leaving the possibility
that in a longer run the CV risk of these two conditions
becomes similar opening to further investigations. This is
the case also for the possibility that the lower CV risk of
statin-induced diabetes is accounted for a large protective
effect of the drug, whose persistence over periods longer than
those available in our study must be tested.
In summary, our data confirm that there is a definite
increase in the development of diabetes with statin therapy.
They suggest, however, that a diabetes that is likely to be
induced by statins is not associated with a clear modification
of macrovascular risk. Trials reflecting the clinical relevance
of treatment-induced diabetes mellitus regarding macrovas-
cular complications are required to confirm this finding.
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